<?xml version="1.0" encoding="UTF-8"?>
<p>Hoelzer et al. (2008) and Shackelton et al. (2005) previously reported that the CPV genomic substitution rate was similar to that of RNA viruses, and the earliest type of CPV-2 was replaced by three main subspecies—CPV-2a, CPV-2b, and CPV-2c—in just a few years [
 <xref rid="B4-viruses-11-00742" ref-type="bibr">4</xref>,
 <xref rid="B8-viruses-11-00742" ref-type="bibr">8</xref>,
 <xref rid="B9-viruses-11-00742" ref-type="bibr">9</xref>,
 <xref rid="B10-viruses-11-00742" ref-type="bibr">10</xref>]. Despite the widespread use of inactivated or live attenuated vaccines, the emergence of antigenic variants and the influence of maternal antibodies have contributed to questioning the efficacy of commercial vaccines [
 <xref rid="B6-viruses-11-00742" ref-type="bibr">6</xref>,
 <xref rid="B7-viruses-11-00742" ref-type="bibr">7</xref>]. In addition, there are no suitable antiviral drugs available for specific treatment of CPV infections. Therefore, the only treatment options for the infection are supportive and symptom-based care [
 <xref rid="B11-viruses-11-00742" ref-type="bibr">11</xref>,
 <xref rid="B12-viruses-11-00742" ref-type="bibr">12</xref>,
 <xref rid="B13-viruses-11-00742" ref-type="bibr">13</xref>]. Thus, it is important to obtain antiviral drugs for potential therapeutic use in canine parvoviral diarrhea.
</p>
